beta
IA Trial Radar
El ensayo clínico NCT06018194 para Enfermedad de la arteria coronaria está reclutando. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí.
Un ensayo coincide con los criterios de filtro
Vista de tarjeta

ELUCIDATE FFRct Study

Reclutando
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el ensayo' para ver y discutir la información del ensayo en el idioma que haya seleccionado.
El estudio clínico NCT06018194 es un ensayo observacional para Enfermedad de la arteria coronaria. Su estado actual es: reclutando. El ensayo se inició el 1 de septiembre de 2023, con el objetivo de reclutar a 350 participantes. Dirigido por Elucid Bioimaging Inc., se espera que finalice el 31 de julio de 2024. Los datos se actualizaron por última vez en ClinicalTrials.gov el 20 de febrero de 2024.
Resumen
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).

Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

Descripción detallada
Invasive fractional flow reserve is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decision-making regarding coronary revascularization in patients with stable clinical presentations. Fractional flow reserve derived from coronary computed tomography angiography (FFRct) using computational fluid dynamic (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on CCTA. However, CFD-based FFRct is calculated based predominately on detailed coronary lumen geometry. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen geometry, significantly impacts the vasodilatory capacity of the coronary endothelium.

Preliminary studies suggest that invasive FFR can be accurately estimated based on the quantification of coronary plaque burden and the assessment of plaque composition. Previously, the investigators have demonstrated that a novel plaque-based FFRct approach, using a histologically validated software (ElucidVivoTM) for the measurement of plaque morphology (volume, plaque risk characteristics, and stenosis) to train a deep-learning model, was shown to be accurate and superior to lumen stenosis for predicting invasive FFR in a single-site feasibility study.

In this study, the investigators seek to assess the diagnostic accuracy of the Elucid plaque-based FFRct software to estimate invasive FFR in patients at multiple centers.

Título oficial

The ELUCIDATE FFRct Study

Condiciones médicas
Enfermedad de la arteria coronaria
Publicaciones
Artículos científicos y trabajos de investigación publicados sobre este ensayo clínico:
Otros ID del ensayo
  • 3-ST-03-03
Número del NCT
Inicio del ensayo (real)
2023-09-01
Última actualización
2024-02-20
Fecha de finalización (estimada)
2024-07-31
Inscripción (prevista)
350
Tipo de estudio
Observacional
Estado general
Reclutando
Palabras clave
coronary computed tomographic angiography
coronary CTA
cardiac CT
fractional flow reserve
plaque
Brazos / Intervenciones
Grupo de participantesIntervención/Tratamiento
Low FFR
Invasive FFR \<= 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
High FFR
Invasive FFR \> 0.80
Elucidvivo
Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
Resultado primario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Sensitivity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Specificity of FFRct versus invasive FFR for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Resultado secundario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Sensitivity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Specificity of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Area under the receiver-operating characteristic curve (AUC) of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Accuracy of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Negative predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-vessel
1 day
Positive predictive value of FFRct for detecting invasive FFR ≤ 0.80
Per-patient
1 day
Criterios de elegibilidad

Criterios de edad
Adulto, Adulto mayor
Edad mínima
18 Years
Criterios de sexo
Todos

- Adults >=18 years with at least one 30-90% stenosis on CCTA (>64- detector row) performed within 60 days of undergoing invasive FFR.

  • History of coronary revascularization with coronary artery bypass graft (CABG) surgery and/or percutaneous coronary intervention (PCI) (stent or balloon angioplasty) prior to CCTA and invasive FFR.
  • History of myocardial infarction prior to CCTA and invasive FFR.
  • Known complex congenital heart disease.
  • Existing pacemaker or internal defibrillator lead implantation(s).
  • Existing prosthetic heart valve.
  • Absence of CCTA Digital Imaging and Communications in Medicine (DICOM) data for analysis.
  • Absence of invasive coronary angiography imaging or adequate description defining the position of the invasive FFR wire location.
  • Poor CCTA image quality that does not meet Elucid image processing requirements for plaque and FFRct.
  • Absence of study date for CCTA or invasive FFR.
  • Interval clinical myocardial infarction, diagnosis of decompensated heart failure, stroke, or coronary revascularization procedure between CCTA and invasive FFR.
  • Non-diagnostic CCTA or invasive FFR. Studies where the results of the study were deemed non-diagnostic for clinical decision-making will be excluded.
  • CCTA or invasive FFR studies performed prior to 1 January 2016.
Elucid Bioimaging Inc. logoElucid Bioimaging Inc.
Lundquist Institute at Harbor-UCLA Medical Center logoLundquist Institute at Harbor-UCLA Medical Center
Contactos centrales del ensayo
Contacto: Todd C Villines, MD, 978-468-0508, [email protected]
Contacto: John Aluru, MBBS, 978-468-0508, [email protected]
9 Sitios del ensayo en 1 países

California

Cardiovascular Medical Group of Southern California, Beverly Hills, California, 90210, United States
Ronald P Karlsberg, MD, Contacto
Aún no recluta

Georgia

Piedmont Healthcare, Atlanta, Georgia, 30309, United States
Venkateshwar Polsani, MD, Contacto
Aún no recluta

Indiana

Parkview Health, Fort Wayne, Indiana, 46845, United States
Dustin Thomas, MD, Contacto
Aún no recluta

Kansas

Midwest Heart and Vascular Specialists, Overland Park, Kansas, 66211, United States
Stephen A Bloom, MD, Contacto
Reclutando

New Jersey

Valley Health System, Ridgewood, New Jersey, 07450, United States
Himanshu Gupta, MD, Contacto
Aún no recluta

Ohio

Cleveland Clinic, Cleveland, Ohio, 44195, United States
Milind Desai, MD, MBA, Contacto
Aún no recluta

Tennessee

Centennial Heart, Nashville, Tennessee, 37203, United States
David Huneycutt, MD, Contacto
Aún no recluta
Ascension Medical Group, Nashville, Tennessee, 37205, United States
Andrew O Zurich, MD, Contacto
Aún no recluta

Virginia

University of Virginia, Charlottesville, Virginia, 22908, United States
Patricia Rodriguez-Lozano, MD, Contacto
Reclutando